Corning Incorporated · NYSE:GLW

Corning — Technical Presentation (October 2007)

25 slides from Corning's technical presentation, October 2007

  1. Slide 1: Application of the Corning Epic System to label-free functional GPCR assays

    ® ® Application of the Corning Epic System to label-free functional GPCR assays Kathy Dodgson Lead Generation Biology AstraZeneca R&D Charnwood

  2. Slide 2: Overview

    Overview • Outline of the technology • Application to all classes of G-protein • Endogenous receptors • Establishing a screening assay for a muscarinic receptor • Summary

  3. Slide 3: Corning Epic System

    ® ® Corning Epic System • A label-free drug screening system ¾ An SBS-standard 384-well microplate with optical biosensors ¾ An HTS-compatible microplate reader LOPAC Screening Plate number 1 1uM LOPAC (1st addition) 400.0 300.0 200.0 Response (pm) + = 100.0 0.0 -100.0 0 10 20 30 40 50 60 70 80 90 1

  4. Slide 4: The Biosensor

    The Biosensor • The substrate grating is covered with a thin dielectric layer; this forms the resonant waveguide grating. • The sensor is illuminated with many wavelengths. • Only a “single” wavelength that is resonant with the waveguide grating structure is strongly reflected. • A change in the ind

  5. Slide 5: The Biosensor

    The Biosensor • The Epic® System measures refractive Cell-Based Assays index changes at the sensor surface Mass Cell Redistribution ¾ Light of the resonant wavelength couples into, and propagates down the waveguide. ¾ A portion of the resonant wavelength extends into the first few hundred nanometers

  6. Slide 6: Integrated Epic System

    Integrated Epic® System Astrazeneca?

  7. Slide 7: Cell-based assay examples

    Cell-based assay examples Astrazeneca?

  8. Slide 8: Assay Procedure

    Assay Procedure • Cells are plated onto the EPIC assay plate and allowed to adhere O/N ¾ Uncoated standard plates for endogenous cells ¾ Fibronectin coated plates for HEK and CHO clonal lines • Prior to assay the cell media is aspirated (Tecan Power Washer) and replaced with assay buffer (HBSS, 20mM

  9. Slide 9: Example of a Gq Receptor

    Example of a Gq Receptor EC80 400 buffer 350 300 250 wavelegth shift (pm) 200 Agonist buffer 150 mean 308 -8 100 EC50 = 19nM stdev 20 10 50 Z' 0.72 0 -50 0.01 0.1 1 10 100 1000 10000 100000 [agonist] (nM)

  10. Slide 10: CHO WT comparison

    CHO WT comparison CHO Gq 300 300 250 200 200 response (pm) 150 CHO clone EC50 = 24nM CHO WT EC50 = IA 100 100 50 0 0 1E-4 1E-3 0.01 0.1 1 10 [agonist] (uM) CHO WT 100 • CHO WT cells did not generate a response to the agonist. 0 • Both cell types responded to ATP (not shown)

  11. Slide 11: Example of a Gi Receptor

    Example of a Gi Receptor EC80 300 250 200 response (pm) 150 buffer EC50 = 2.2nM 100 50 0 10 20 30 0 Dose response 0.01 0.1 1 10 [agonist] (nM) • HEK cell line • Chemokine receptor • EC50 similar to other assay formats 0 10 20 30

  12. Slide 12: Effect of Pertussis on Gi response

    Effect of Pertussis on Gi response 100 • Response decreased 80 untreated 100ng/ml pertussis by pre-treatment with 200ng/ml pertussis 60 pertussis toxin % Inhibition 40 • 200 ng/ml PTX 20 decreased the response by 70% 0 0.01 0.1 1 10 [agonist] (nM)

  13. Slide 13: Example of a Gs Receptor

    Example of a Gs Receptor Effect of formoterol on H292 cells (15K/well) 70 50 60 50 40 response (pm) 30 20 0 10 EC50 = 130pM 0 -10 -20 1E-4 1E-3 0.01 0.1 1 10 [agonist] (nM) 0 10 20 30 40 mins • H292 is an epithelial cell line • Cells adhere to uncoated plate • Endogenous Gs response for beta2 recept

  14. Slide 14: Summary of GPCR Responses

    Summary of GPCR Responses Gq response Gi response Gs response 400 50 300 200 200 100 0 100 0 0 -50 0 5 10 15 0 10 20 30 0 10 20 30 40 ® • The EPIC is able to measure distinct responses for the 3 types of GPCR

  15. Slide 15: Endogenous Receptors

    Endogenous Receptors Astrazeneca?

  16. Slide 16: Human Neutrophils

    Human Neutrophils • Human neutrophils were prepared by density gradient centrifugation • They were resuspended in HBSS/HEPES plus 0.1% BSA and plated onto uncoated EPIC assay plates at 80 to 50K/well • The plates were centrifuged briefly • Agonists were prepared in the same buffer system • The effec

  17. Slide 17: Neutrophil Response to IL8

    Neutrophil Response to IL8 25nM 12.5nM 1200 3.2nM 1000 1.6nM 800 Response (pm) 600 0.8nM EC50 = 1nM 400 200 0 -200 0.01 0.1 1 10 [IL8] (nM) 60K neutrophils/well FLIPR EC50 = 1nM

  18. Slide 18: Neutrophil Response to GROα

    Neutrophil Response to GROα 1600 25nM 1400 1200 12.5nM 1000 Response (pm) 800 600 3.2nM EC50 1.4nM 400 1.6nM 200 0 0.8nM -200 0.01 0.1 1 10 [GROalpha] (nM) 60K neutrophils/well FLIPR EC50 = 0.5nM

  19. Slide 19: Screening Assay

    Screening Assay Astrazeneca?

  20. Slide 20: Muscarinic Antagonist Screening

    Muscarinic Antagonist Screening Antagonist • Cells plated out O/N • Cells washed and assay buffer added • Initial baseline read • Compounds added to adherent cells • 0.25% DMSO final • Agonist then added (0.25% DMSO) Buffer controls EC80 control Antagonist (O – P) (L – N) ( B – K)

  21. Slide 21: CHO antagonist rank order

    CHO antagonist rank order 10 9 Run 2 9.5 9 EPIC 8.5 8.5 8 8 7.5 7.5 7 Run 1 7.5 8 8.5 9 7 7.5 8 8.5 9 9.5 10 FLIPR • Five standard compounds were tested on two days • The pIC50 values correlated well with FLIPR data • Equivalent pIC50 values were obtained

  22. Slide 22: CHO Gq Screening Test

    CHO Gq Screening Test 120 100 • 20 wells were spiked with a standard 80 compound at 2 concentrations % Inhibition 60 40 • All the spiked wells were identified 20 • No false positives >20% 0 0 50 100 150 200 250 • The Z’ value was >0.6 -20 Well

  23. Slide 23: Correlation of Hits

    Correlation of Hits 150 • A compound plate 125 containing 320 Correlated hits compounds was tested 100 in duplicate on the 75 same day • Line of correlation 50 R2 = 0.81 25 0 -25 -25 0 25 50 75 100 125 150 32726

  24. Slide 24: Summary

    Summary ® • We have shown that the Epic System can measure specific functional responses to cloned Gi, Gs and Gq GPCRs, with distinct temporal relationships. • The technology is also sensitive enough to measure endogenous responses offering the possibility of performing assays in a biologically rele

  25. Slide 25: Acknowledgements

    Acknowledgements AstraZeneca • Philip Rawlins • Martin Coldwell • Malbinder Fagura • Dave Laughton CORNING • Denis To Van • Alice Gao • Ute Vespermann

Corning — Technical Presentation (October 2007) on 6ix